{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-22-000004","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.868380+00:00","generated_at":"2026-06-26T23:57:06.877143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroPace reports 2021 revenue $45.2M (+10% YoY), Q4 net loss $10.7M","bullets":["Full-year initial implant revenue $33.7M (+20% YoY); replacement revenue $11.5M (-12% YoY).","Q4 total revenue $11.0M (+2% YoY); net loss $10.7M vs $4.6M loss in Q4 2020.","FDA approved IDE for pivotal study in drug-resistant primary generalized epilepsy.","2022 guidance: full-year revenue $45-48M, initial implant revenue $39-42M.","Cash and marketable securities $115.6M; long-term borrowings $49.8M as of Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-22-000004","json":"https://secwatch.observer/filing/0001528287-22-000004.json","markdown":"https://secwatch.observer/filing/0001528287-22-000004.md","text":"https://secwatch.observer/filing/0001528287-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000004/0001528287-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000004/npce-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:57:06.877143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}